ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
Portfolio Pulse from
Intra-Cellular Therapies (ITCI) has submitted a supplemental New Drug Application (sNDA) to the FDA for the expanded use of Caplyta as an adjunctive therapy for Major Depressive Disorder (MDD) in adults. This move could potentially broaden the market for Caplyta if approved.
December 04, 2024 | 6:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies has submitted an sNDA to the FDA for Caplyta's use in treating MDD, which could expand its market if approved.
The submission of an sNDA for Caplyta to treat MDD could lead to an expanded market for the drug, potentially increasing ITCI's revenue. The FDA's decision will be crucial, and a positive outcome could positively impact ITCI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100